Evidence map›Paper›PMID 41031725›Full record

ArticleCancer medicine2025

Peptide Modulation Overrides Glycan Synergy in Gold Nanoparticle-Based Vaccines for Cancer Immunotherapy.

Narumi Harada, Mayumi Niimura, Yasuhisa Sakamoto, Akihiro Nita, Mayuko Shimoda, Shiho Wada, Koki Murata, Masahiro Wakao, Tomomi Kamba, Hiroyuki Shinchi and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Narumi HaradaDepartment of Molecular and Medical Pharmacology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.ORCID https://orcid.org/0000-0002-4100-0184
Mayumi NiimuraDepartment of Molecular and Medical Pharmacology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Yasuhisa SakamotoDepartment of Molecular and Medical Pharmacology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Akihiro NitaDivision of Cellular Dynamics, Medical Research Laboratory, Institute of Integrated Research, Institute of Science Tokyo, Tokyo, Japan.
Mayuko ShimodaDepartment of Molecular and Medical Pharmacology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Shiho WadaDepartment of Engineering, Chemistry and Biotechnology Program, Graduate School of Science and Engineering, Kagoshima University, Kagoshima, Japan.
Koki MurataDepartment of Engineering, Chemistry and Biotechnology Program, Graduate School of Science and Engineering, Kagoshima University, Kagoshima, Japan.
Masahiro WakaoDepartment of Engineering, Chemistry and Biotechnology Program, Graduate School of Science and Engineering, Kagoshima University, Kagoshima, Japan.
Tomomi KambaDepartment of Urology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Hiroyuki ShinchiDepartment of Engineering, Chemistry and Biotechnology Program, Graduate School of Science and Engineering, Kagoshima University, Kagoshima, Japan.
Toshiro MoroishiDepartment of Molecular and Medical Pharmacology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.ORCID https://orcid.org/0000-0001-6419-3882

Funding

Hoansha FoundationJapan Agency for Medical Research and Development JP22cm0106382Japan Agency for Medical Research and Development JP22gm6210030Japan Science and Technology Agency JPMJFR226JJapan Science and Technology Agency JPMJPR17HAJapan Society for the Promotion of Science 24H00864Japan Society for the Promotion of Science 24H00865Takeda Science Foundation
6 · The paper itself

Abstract

backgroundWe have previously developed a gold nanoparticle (GNP)-based anti-cancer immunotherapy, termed integrated glyco-nanovaccine (iGN). The iGN is composed of GNPs conjugated to a synthetic toll-like receptor (TLR) 7 ligand, an antigen peptide, and a mannose sugar chain. However, the effect of the combination of different sugar chains and antigen peptides on iGN-mediated anticancer immunotherapy remains to be elucidated.

objectiveWe compared the anti-tumor effects of two different sugar chains: α-mannose and sialic acid.

resultsWe showed that not only the sugar chain but also the antigen peptide plays a pivotal role in iGN uptake by immune cells. In contrast to α-mannose, which promoted GNP internalization by bone marrow-derived dendritic cells (BMDC), sialic acid modification resulted in limited cellular uptake. The integration of major histocompatibility complex class I-restricted ovalbumin peptides drastically changed this cellular recognition pattern, particularly for sialic acid-modified iGN. The peptide largely improved the uptake of nanoparticles, delivery of the TLR 7 ligand, and subsequent activation of the type I interferon pathway in BMDC. Sialic acid-modified iGN demonstrated comparable induction of CD8

conclusionsThese results indicate that antigens, and not only the sugar chain, critically determine both the cellular internalization and immunotherapeutic efficacy of iGNs. This study presents a new design principle for glyco-nanovaccines, where peptides override glycan synergy and determine therapeutic efficacy.

Indexed as

Cancer VaccinesGoldImmunotherapyMetal NanoparticlesNeoplasmsPeptidesPolysaccharidesAnimalsCD8-Positive T-LymphocytesCell Line, TumorDendritic CellsFemaleHumansMannoseMiceMice, Inbred C57BLCancer VaccinesGoldMannoseN-Acetylneuraminic AcidPeptidesPolysaccharidesantigen peptidegold nanoparticleimmunotherapysugar chainTLR7 ligand

Identifiers

PMID41031725
PMCPMC12486328

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.